Research map: Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study

Back to the article

Papers in this map

  1. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice · Robert Trevethan · 2017 · 1669 citations · Cited by this paper
  2. Chemotherapy-Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors, and Management Patterns · 2026 · Related
  3. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial · David Planchard · 2017 · 1391 citations · Cited by this paper
  4. Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling · 2026 · Related
  5. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) · Fabrice Barlési · 2016 · 1014 citations · Cited by this paper
  6. Transcriptionally Informed Nucleosome Profiling of Circulating Cell-Free DNA Predicts Breast Cancer Recurrence · 2026 · Related
  7. Liquid biopsy: current technology and clinical applications · Mina Nikanjam · 2022 · 938 citations · Cited by this paper
  8. Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway · 2026 · Related
  9. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Lizza E.L. Hendriks · 2023 · 859 citations · Cited by this paper
  10. Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapy · 2026 · Related
  11. Multiple Imputation · Peng Li · 2015 · 655 citations · Cited by this paper
  12. Natural Autoantibodies Negatively Correlate with Hepatocellular Carcinoma Incidence in Cirrhosis · 2026 · Related
  13. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin · Ryan Woodhouse · 2020 · 522 citations · Cited by this paper
  14. BRAF Inhibition–Associated Nuclear Remodeling is Linked to Cancer-Associated Fibroblast Activation · 2026 · Related
  15. Bootstrap inference when using multiple imputation · Michael Schomaker · 2018 · 468 citations · Cited by this paper
  16. Tissue Context Shapes Distinct Premalignant Outcomes in an HPV16 E6/E7-Mutant Pik3ca Transgenic Mouse Model · 2026 · Related
  17. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer · Feifei Cheng · 2016 · 407 citations · Cited by this paper
  18. Glioblastoma subtypes exhibit distinct migration mechanics and immune responses · 2026 · Related
  19. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies · Yoshiaki Nakamura · 2020 · 379 citations · Cited by this paper
  20. Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer · Stephanie Cardarella · 2013 · 377 citations · Cited by this paper
  21. Clinical Development of BRAF plus MEK Inhibitor Combinations · Vivek Subbiah · 2020 · 360 citations · Cited by this paper
  22. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer · Gregory J. Riely · 2023 · 126 citations · Cited by this paper
  23. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer · Luping Lin · 2014 · 107 citations · Cited by this paper
  24. Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples · Hatim Husain · 2022 · 103 citations · Cited by this paper
  25. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation · Christian Diego Rolfo · 2024 · 96 citations · Cited by this paper
  26. Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure · Takahisa Kawamura · 2016 · 92 citations · Cited by this paper
  27. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? · Laura S. Bonanno · 2022 · 83 citations · Cited by this paper
  28. Regulatory implications of ctDNA in immuno-oncology for solid tumors · Paz J. Vellanki · 2023 · 68 citations · Cited by this paper
  29. The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients · Paul M Hofman · 2019 · 61 citations · Cited by this paper
  30. Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back · Annapaola Mariniello · 2025 · 43 citations · Cited by this paper
  31. Biopsy frequency and complications among lung cancer patients in the United States · Yichen Zhang · 2020 · 43 citations · Cited by this paper
  32. Lung Cancer: Targeted Therapy in 2025 · Nicole C. Bouchard · 2025 · 39 citations · Cited by this paper
  33. Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients · Richard S.P. Huang · 2021 · 31 citations · Cited by this paper
  34. Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report · Gregory J. Riely · 2025 · 16 citations · Cited by this paper
  35. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing · Alberto Ranghiero · 2023 · 15 citations · Cited by this paper
  36. The rapidly changing field of predictive biomarkers of non-small cell lung cancer · László Tóth · 2024 · 13 citations · Cited by this paper
  37. Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer · Melissa Lynne Johnson · 2025 · 13 citations · Cited by this paper
  38. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort · Guan Hui Tricia Lim · 2022 · 12 citations · Cited by this paper
  39. Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials · Sophie M. Ernst · 2025 · 12 citations · Cited by this paper

Source: OpenAlex (CC0)